PHDA continues to collaborate with the University of Manitoba in a Randomized Controlled Clinical Trial with the aim of developing epidemic control strategies for HIV. The study has 300 FSW enrolled in the SWOP program within Majengo, Kariobangi and Donholm clinics, in 3 phases over 3 years. Each phase has 100 women in 3 groups with different dosage of Aspirin as follows: 81mg, 325mg, no drug.
Objectives
- To determine the effect of Aspirin on HIV target cells in female sex workers (FSW)
- To determine the dosage of Aspirin most effective at inducing immune quiescence in FSW.
Project Initiated 2022
The study started in January 2022 and will continue for three years and end in 2024
Partnerships
Asprin study is funded by Canadian Institute of health research